AssetMemo

Therapeutic area

Respiratory

Obstructive airway diseases, interstitial lung disorders, pulmonary hypertension, and chronic respiratory illnesses.

Core & active disease programs

Asthma
$107.9B attributable cost
$45.6B$ drug spend
92 assets · 1 indication
Chronic Obstructive Pulmonary Disease
$48.0B attributable cost
$20.9B$ drug spend
44 assets · 1 indication
Idiopathic Pulmonary Fibrosis
$8.8B+ attributable cost
4 assets · 2 indications
Provisional & emerging programs (5)Early clinical pipeline & single-asset indications
Cystic Fibrosis
8 assets
Pulmonary Arterial Hypertension
5 assets
Allergic Bronchopulmonary Aspergillosis
1 asset
Pulmonary Alveolar Proteinosis
1 asset
Pulmonary Hypertension Associated with Interstitial Lung Disease
1 asset

All assets in Respiratory

← all areas